×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
SESSION 2
Session Chair(s)
Tomas Salmonson, DrMed, PhD
Partner
Critical Path Institute, United States
This session will talk about how the M2 expert group will impact on drug development and on other ICH guidelines. Translation of standards to real impact for drug discovery and impacts on public health. This session will focus on the changes that S1, S5, and S11 will introduce.
Speaker(s)
M2 Electronic Standards
Joris Kampmeijer
Medicines Evaluation Board , Netherlands
Information Processing Department
S Series: Changing paradigms in non-clinical drug development
Jan Willem van der Laan, PhD
Medicines Evaluation Board, Netherlands
Senior Assessor Pharmacology and Toxicology